1. Home
  2. VYGR vs EPSN Comparison

VYGR vs EPSN Comparison

Compare VYGR & EPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • EPSN
  • Stock Information
  • Founded
  • VYGR 2013
  • EPSN 2005
  • Country
  • VYGR United States
  • EPSN Canada
  • Employees
  • VYGR N/A
  • EPSN N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • EPSN Oil & Gas Production
  • Sector
  • VYGR Health Care
  • EPSN Energy
  • Exchange
  • VYGR Nasdaq
  • EPSN Nasdaq
  • Market Cap
  • VYGR 164.3M
  • EPSN 175.3M
  • IPO Year
  • VYGR 2015
  • EPSN N/A
  • Fundamental
  • Price
  • VYGR $3.20
  • EPSN $7.50
  • Analyst Decision
  • VYGR Strong Buy
  • EPSN Strong Buy
  • Analyst Count
  • VYGR 8
  • EPSN 1
  • Target Price
  • VYGR $14.33
  • EPSN $7.00
  • AVG Volume (30 Days)
  • VYGR 715.4K
  • EPSN 380.1K
  • Earning Date
  • VYGR 08-05-2025
  • EPSN 08-12-2025
  • Dividend Yield
  • VYGR N/A
  • EPSN 3.33%
  • EPS Growth
  • VYGR N/A
  • EPSN N/A
  • EPS
  • VYGR N/A
  • EPSN 0.20
  • Revenue
  • VYGR $66,958,000.00
  • EPSN $39,699,172.00
  • Revenue This Year
  • VYGR N/A
  • EPSN $41.35
  • Revenue Next Year
  • VYGR $78.88
  • EPSN N/A
  • P/E Ratio
  • VYGR N/A
  • EPSN $37.31
  • Revenue Growth
  • VYGR N/A
  • EPSN 35.21
  • 52 Week Low
  • VYGR $2.65
  • EPSN $4.95
  • 52 Week High
  • VYGR $9.55
  • EPSN $8.50
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 51.88
  • EPSN 47.02
  • Support Level
  • VYGR $2.83
  • EPSN $7.25
  • Resistance Level
  • VYGR $3.43
  • EPSN $8.50
  • Average True Range (ATR)
  • VYGR 0.19
  • EPSN 0.26
  • MACD
  • VYGR 0.01
  • EPSN -0.10
  • Stochastic Oscillator
  • VYGR 55.22
  • EPSN 20.00

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About EPSN Epsilon Energy Ltd. Common Share

Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.

Share on Social Networks: